Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limertinib Plus Radiotherapy in First-Line EGFR-Mutant NSCLC With Brain Metastases
NCT07413952Phase 2Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of limertinib in non-small cell lung cancer (NSCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
limertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07413952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07413952.